BD expands cancer diagnostics portfolio with acquisition of Cytognos

BD (Becton, Dickinson and Company) has completed the acquisition of Cytognos, a privately held company headquartered in Salamanca, Spain, specialising in flow cytometry solutions for blood cancer diagnosis, minimal residual disease

(MRD) detection and immune monitoring research for blood diseases. The acquisition of Cytognos accelerates BD’s strategy to support chronic disease management by expanding its portfolio of blood cancer diagnostics, immune assessment tests and informatics to address patient, clinician and care provider needs to better understand the immune system, immune response and MRD. By monitoring for MRD, lab managers and physicians can detect low levels of cancer cells following treatment that alerts them if the disease is still present or if there is a signal of recurrence. This is a key element of the patient care continuum that helps clinicians and physicians recognize when cancer recurs and aids in the timely treatment of patients.